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creased Mg excretion in urine and caused hypomagnesemia shortly
after initiating administration, the effect was more signiﬁcant with
tacrolimus than with CSA.
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POSACONAZOLE (POS) SALVAGE THERAPY ALLOWS SUCCESSFUL AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN
PATIENTS WITH REFRACTORY INVASIVE MOLD INFECTIONS
Mullane, K.1, Toor, A.2, Rodriguez, T.2, Kalnicky, C.1, Klein, J.2,
Stiff, P.2 1Department of Internal Medicine, Section of Infectious Dis-
eases, and Bone Marrow Transplant Program, Loyola University Stritch
School of Medicine, Maywood, IL.
In patients with hematologic malignancies, invasive fungal infec-
tion (IFI) causes signiﬁcant morbidity and mortality, often posing
a contraindication to allogeneic HSCT. The overall rate of IFI
appears to be increasing even with use of antifungal prophylaxis.
Posaconazole (POS) is an extended-spectrum triazole with activity
against many fungal pathogens, including resistant molds. In this
open-label compassionate use salvage antifungal therapy study, 3
subjects with IFI caused by uncommon molds (Alternaria spp.
[rhinopulmonary], Paecilomyces lilacinus [pulmonary], and Zygomy-
cetes spp. [pulmonary and pericardial]) underwent allogeneic
HCST during POS therapy. Two patients had acute myelogenous
leukemia (AML), and 1 patient had multiple myeloma (MM).
Before starting POS therapy, all 3 patients had failed prophylaxis
with ﬂuconazole and salvage therapy with voriconazole (n  3),
caspofungin (n  2), and liposomal amphotericin B (n  3).
Median duration of antifungal therapy before starting POS was 2.5
months (range, 1.5–9 months). Two patients also required surgical
intervention for initial control. Median duration of POS therapy
before HSCT was 5 months (range, 1.5–6 months).
Treatment resulted in complete resolution of IFI in 1 patient and
improvement in 2 patients (based on follow-up CT scanning). The
patient with Zygomyces spp. had resolution of fungal pericarditis.
Subsequently, the 2 AML patients underwent conventional my-
eloablative conditioning, and the one MM patient received a re-
duced intensity regimen. Two patients also received antithymocyte
globulin. The stem cell sources were unrelated umbilical cord
blood, unrelated donor bone marrow, and related donor PBSC.
Graft-versus-host disease prophylaxis consisted of tacrolimus in 3
patients, methotrexate in 1 patient, and methylprednisolone in 1
patient.
Median time to myeloid engraftment was 13 days (range, 11–20
days). At 3 months posttransplantation, 2 patients are alive without
evidence of IFI. One patient died of recurrent AML 4 months after
transplantation without evidence of IFI. No toxicities were attrib-
utable to POS. Tacrolimus pharmacokinetics remained relatively
unchanged.
This preliminary report demonstrates that POS was effective in
treating invasive mold infections refractory to conventional anti-
fungal therapy, including amphotericin B, in these high-risk indi-
viduals allowing for allogeneic HSCT.
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THE EFFECTS OF HYPERGLYCEMIA ON HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Mosallaei-Benjamin, M., Hamadani, M., Scoﬁeld, H., Holla, P.,
Selby, G. Oklahoma University Health Sciences Center, Oklahoma City,
OK.
Background: Studies of critically ill patients in intensive care
settings have correlated tight glucose control with a substantial
reduction in morbidity and mortality and length of hospital stay.
The impact of hyperglycemia in the hematopoietic stem cell trans-
plantation (HSCT) population has not been studied. The aim of
this study was to investigate the relationship between hyperglyce-
mia and morbidity and mortality in HSCT patients. Methods: A
retrospective chart review of 98 consecutive adult patients (age 
17 years) admitted between January 1, 2002 and October 31, 2003
to the University of Oklahoma Health Sciences Center BMTU
was performed. Patients who received myeloablation followed by
autologous (n  48) or allogeneic (n  47) HSCT were analyzed
in separate groups. Mean inpatient plasma glucose values were
used to stratify the patients into euglycemic (glucose  126 mg/
dL) and hyperglycemic (glucose  126 mg/dL) groups. The pri-
mary outcome was length of inpatient stay (LOS) from day 0 until
discharge. Secondary outcome measures were number of infections
indicated by positive blood cultures; evidence of venous line infec-
tion; urinary tract infection; Clostridium difﬁcile infection; radio-
graphic evidence of pneumonia; number of days on nonprophylac-
tic antibiotics; total number of simultaneous antibiotics used;
engraftment time (ANC  500); and number of febrile days (tem-
perature  101°F). A tertiary outcome measure was in-hospital
death. Results: LOS for the alloHSCT patients was signiﬁcantly
longer (P .02) in the hyperglycemic group (mean, 34.0 days) than
in the euglycemic group (mean, 24.7 days). The hyperglycemic
group had signiﬁcantly higher in-patient mortality (P  .0036),
number of infections (P .0015), and number of days on nonpro-
phylactic antibiotics (P  .0078) than the euglycemic group. LOS
was also signiﬁcantly (P  .01) longer for the hyperglycemic
autoHSCT patients (mean, 31.33 days) than for the euglycemic
patients (mean, 18.30 days). Hyperglycemic autoHSCT patients
also demonstrated a signiﬁcantly higher number of documented
infections (P  .028). Conclusions: This retrospective study in-
dicates that hyperglycemia is strongly associated with increased
mortality and morbidity and LOS in HSCT patients. Randomized
prospective studies are necessary to elucidate the beneﬁts that strict
glucose control may provide during hematopoietic stem cell trans-
plantation.
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SHARED MEDICAL APPOINTMENTS (SMA): IMPLEMENTATION IN THE
BONE MARROW TRANSPLANTATION CLINIC
Meehan, K.R., Root, L., Kimtis, E.A., Patchett, L., Hill, J.M. Dart-
mouth-Hitchcock Medical Center, Lebanon, NH.
SMAs were implemented to provide patients increased time with
their care providers in an interactive setting, while sharing expe-
riences with other patients. These appointments allow care pro-
viders an opportunity to see more patients with similar needs in a
shorter period of time. SMAs have generally been limited to gen-
eral medicine or a few of its subspecialties, and have not been used
within the BMT population. Autologous stem cell recipients at our
center receive posttransplantation restaging evaluations at day 100,
every 6 months for 2 years, and then annually.
Eligible patients between 100 days and 2 years posttransplanta-
tion were contacted to participate in the SMA. Each patient’s
completed evaluation was forwarded to the BMT coordinator and
entered into the electronic templated note that was generated
before the visit. On the day of the SMA, brief exams and discussion
of conﬁdential issues were performed for each patient by a care
provider (2 MDs/1 NP) in a private ofﬁce, while the BMT coor-
dinator served as facilitator and prioritized patient questions raised
by the group.
On completion of the exams, the 3 care providers met with all of
the patients and answered questions in a group setting. Patients
were surveyed on completion of the SMA visit to evaluate the
format. Although 16 patients were eligible to participate in the
SMA, based on the timing of their workup and the SMA appoint-
ment, it was limited to 10 patients (7 with MM, 1 with AML, and
2 with NHL), to facilitate efﬁciency and ease of patient participa-
tion. Questions during the group meeting were general and appli-
cable to all patients, addressing such issues as hormone replace-
ment therapy, timing of vaccinations, and optimizing
posttransplantation quality of life. At completion of the 2.5-hour
visit, a survey was distributed, which indicated that patients pre-
ferred the SMA over a routine ofﬁce visit and will return again.
The BMT patient population is ideal for a tertiary care SMA.
These patients are highly motivated and issues discussed during the
group meeting were pertinent to all autologous transplantation
recipients, regardless of diagnosis. The SMA allows the patient to
spend a considerable amount of time with their care providers,
while providing the care providers an opportunity to discuss gen-
eral health questions pertinent to all transplantation patients in one
appointment. Our BMT program is expanding its SMA efforts by
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